Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib/Dexamethasone Therapy in Relapsed/Refractory Cutaneous T-cell Lymphoma
NCT03487133Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Sep 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in cutaneous T-cell lymphoma (CTCL), sponsored by Samsung Medical Center. Started Sep 2017; status: completed.
02
Drugs
bortezomib
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03487133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487133.